
Cracking the code for building a West Coast biotech.

Cracking the code for building a West Coast biotech.

Leading through tough IPR terrain.

In a knowledge industry like biopharma, people are the intangible asset that marks the difference between a status quo or standout performance. Pharm Exec recently convened a panel of industry team leaders and HR specialists at St. Joseph’s University Haub School of Business to parse out some useful best practices in three key areas: talent recruitment and retention; skills training; and workforce diversity.

Rising to the global challenge.

A quick countdown of this year's Top 50 movers and shakers.

The leap from from bench to boardroom.

Juventas's CEO pins his company's success on recruiting top tier talent and maintaining an open culture.

Finding the R&D sweet spot.

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

Pharmaceutical Executive
Expert panel on rare disease highlights the challenges of serving expectant patients in this uniquely complex market access environment.

Pharm Exec's Emerging Pharma Leaders 2013

Pharmaceutical Executive
Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres, whose career demonstrates that doing right starts with finding-and being-yourself.

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

Following Pharm Exec’s recent profile of the Express Scripts CMO, Dr. Steve Miller adds some further thoughts - on health reform, cost-effectiveness research, pharma’s reputation, and the obligations of government - to his incisive critique of industry pricing practises.

Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

With a new name and a veteran CEO, Deborah Dunsire, at the helm, FORUM Pharmaceuticals's flag is waving high in the increasingly solitary struggle against CNS disease.

For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal-it's today's fact of life

Patrick Lindsay, president of UBC sits down with Editorial Director William Looney to discusses the issues UBC confronts as it offers support services to pharmaceutical companies

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. PharmExec talks to the CEO of one such company, Eugene Williams of Dart Therapeutics.

Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.

This year's HBA Woman of the Year is Merck's Bridgette Heller of Merck Consumer Care.

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.

Pharmaceutical Executive
Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.

Are there parallels between milk and medicine? To David Ford, a native New Zealander who now runs Sanofi's North America human resources operations, the answer is a qualified yes.

Pharma's Baby Boomer era is over - now it's the Generation X-ers' turn, says Georg Toufar, Chief Marketing Officer and Board Director of Mundipharma International Limited.